Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could tame blistering skin disease without high steroid doses

NCT ID NCT06696716

Ongoing Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This phase 3 study tests an experimental drug called tirabrutinib for people with pemphigus, a rare autoimmune disease that causes painful blisters on skin and mucous membranes. The trial enrolls 34 adults whose disease is not well controlled by steroids. Participants receive either tirabrutinib or a placebo pill daily, plus a low dose of steroids. The main goal is to see if the drug helps achieve and maintain remission (no or minimal blisters) for at least 8 weeks while keeping steroid use low.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tirabrutinib (a drug taken as a pill that targets a protein involved in immune attacks)
What this could lead to
If successful, this could offer a new treatment option for people with pemphigus that doesn't respond well to steroids, potentially helping control blisters with less steroid use.
What could go wrong
This is a small early-phase 3 trial with only 34 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects like infection or allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEMPHIGUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pemphigus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEMPHIGUS STEROID-RESISTANT PEMPHIGUS

Contacts and locations

Locations

  • Ehime University Hospital

    Ehime, Japan

  • Fukushima Medical University Hospital

    Fukushima, Japan

  • Gunma University Hospital

    Gunma, Japan

  • Hokkaido University Hospital

    Hokkaido, Japan

  • Ichinomiya Municipal Hospital

    Aichi, Japan

  • Jichi Medical University Hospital

    Tochigi, Japan

  • Kagoshima University Hospital

    Kagoshima, Japan

  • Kawasaki Medical School Hospital

    Okayama, Japan

  • Keio University Hospital

    Tokyo, Japan

  • Kindai university hospital

    Osaka, Japan

  • Kumamoto University Hospital

    Kumamoto, Japan

  • Kurume University Hospital

    Fukuoka, Japan

  • Nagoya City University Hospital

    Aichi, Japan

  • Niigata University Medical & Dental Hospital

    Niigata, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

  • Saitama Medical Center

    Saitama, Japan

  • Shiga University of Medical Science Hospital

    Shiga, Japan

  • St.Marianna University School of Medicine Hospital

    Kanagawa, Japan

  • Tokai University Hospital

    Kanagawa, Japan

  • Tokyo Medical and Dental University Hospital

    Tokyo, Japan

  • Tokyo Women'ｓ Medical University Hospital

    Tokyo, Japan

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, Japan

  • University of the Ryukyus Hospital

    Okinawa, Japan

  • Yamagata University Hospital

    Yamagata, Japan

  • Yokohama City University Hospital

    Kanagawa, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.